TY - JOUR
T1 - Tacrolimus and Mycophenolic Acid Exposure Are Associated with Biopsy-Proven Acute Rejection
T2 - A Study to Provide Evidence for Longer-Term Target Ranges
AU - Meziyerh, Soufian
AU - van Gelder, Teun
AU - Kers, Jesper
AU - van der Helm, Danny
AU - van der Boog, Paul J. M.
AU - de Fijter, Johan W.
AU - Moes, Dirk Jan A. R.
AU - de Vries, Aiko P. J.
N1 - Funding Information: No funding was received for this work. Publisher Copyright: © 2023 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
PY - 2023/7
Y1 - 2023/7
N2 - Evidence to define target ranges for tacrolimus (Tac) and mycophenolic acid (MPA) exposure after the first year of kidney transplantation is limited. We investigated the association of measurements at 1 year and repeated measurements of real-world Tac-trough levels (C0) and abbreviated area under the curve from zero to 12 hours (AUC0-12h) of Tac and MPA with biopsy-proven acute rejection (BPAR) between years 1 and 3 post-transplant in 968 kidney transplant recipients (KTRs). Thirty-five (3.6%) out of 968 KTRs experienced BPAR. Both Tac-AUC0-12h (hazard ratio (HR): 0.39, 95% confidence interval (CI): 0.30–0.50, P < 0.001), Tac-C0 (HR: 0.46, 95% CI: 0.38–0.57, P < 0.001) and MPA-AUC0-12h at 1 year (HR: 0.80, 95% CI: 0.68–0.94, P = 0.006), as well as repeated measurements of Tac-C0 (HR: 0.70, 95% credibility interval (CrI): 0.61–0.82, P < 0.001), and of MPA-AUC0-12h (HR: 0.75, 95% CrI: 0.62–0.93, P < 0.001) were associated with BPAR. In our population, the recommended target range for Tac-AUC0-12h at 1 year would be 75–95 ng*hour/mL and a Tac-C0 5–7 ng/mL. The Tac-AUC0-12h predicted BPAR better than Tac-C0 and identified KTRs with over- or underexposure despite supposedly adequate Tac-C0. We did not find evidence to recommend another target than the consensus range of 30–60 mg*hour/L for MPA-AUC0-12h after the first year of transplantation. To our knowledge, this is a first study on the simultaneous exposure of Tac and MPA at year 1 and subsequent BPAR up to year 3, which may help define the therapeutic target window for the longer term.
AB - Evidence to define target ranges for tacrolimus (Tac) and mycophenolic acid (MPA) exposure after the first year of kidney transplantation is limited. We investigated the association of measurements at 1 year and repeated measurements of real-world Tac-trough levels (C0) and abbreviated area under the curve from zero to 12 hours (AUC0-12h) of Tac and MPA with biopsy-proven acute rejection (BPAR) between years 1 and 3 post-transplant in 968 kidney transplant recipients (KTRs). Thirty-five (3.6%) out of 968 KTRs experienced BPAR. Both Tac-AUC0-12h (hazard ratio (HR): 0.39, 95% confidence interval (CI): 0.30–0.50, P < 0.001), Tac-C0 (HR: 0.46, 95% CI: 0.38–0.57, P < 0.001) and MPA-AUC0-12h at 1 year (HR: 0.80, 95% CI: 0.68–0.94, P = 0.006), as well as repeated measurements of Tac-C0 (HR: 0.70, 95% credibility interval (CrI): 0.61–0.82, P < 0.001), and of MPA-AUC0-12h (HR: 0.75, 95% CrI: 0.62–0.93, P < 0.001) were associated with BPAR. In our population, the recommended target range for Tac-AUC0-12h at 1 year would be 75–95 ng*hour/mL and a Tac-C0 5–7 ng/mL. The Tac-AUC0-12h predicted BPAR better than Tac-C0 and identified KTRs with over- or underexposure despite supposedly adequate Tac-C0. We did not find evidence to recommend another target than the consensus range of 30–60 mg*hour/L for MPA-AUC0-12h after the first year of transplantation. To our knowledge, this is a first study on the simultaneous exposure of Tac and MPA at year 1 and subsequent BPAR up to year 3, which may help define the therapeutic target window for the longer term.
UR - http://www.scopus.com/inward/record.url?scp=85159132093&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/cpt.2915
DO - https://doi.org/10.1002/cpt.2915
M3 - Article
C2 - 37082913
SN - 0009-9236
VL - 114
SP - 192
EP - 200
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 1
ER -